Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
According to the World Health Organization classification, gliomatosis cerebri (GC) is defined by diffuse neoplastic glial cell infiltration involving at least two lobes of the brain and preserving the underlying neural structures, without individual tumoral mass.1 Because of the diffuse characteristics of the lesion, surgery is often limited to a diagnostic biopsy. Radiotherapy necessarily involves a large volume (most often the whole brain) and results in substantial toxicity. However, a 38-month median survival time has been reported with this treatment and it has been suggested that it may benefit at least some patients.2,3⇓ Up-front chemotherapy has seldom been tested in GC. Recently, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri
- David Schiff, University of Virginia Medical Center Charlottesville VADS4JD@hscmail.mcc.virginia.edu
Submitted March 07, 2003 - Reply to Letter to the Editor
- Marc Sanson, Hopital de la Salpetriere Paris Francem.sanson@psl.ap-hop-paris.fr
Submitted March 07, 2003
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Fabricio Ferreira de Oliveira and Dr. Alan Cronemberger Andrade
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Special Articles: Invited Articles
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomasWarren P. Mason, J. Gregory Cairncross et al.Neurology, July 28, 2008 -
Articles
Initial chemotherapy in gliomatosis cerebriM. Sanson, S. Cartalat-Carel, S. Taillibert et al.Neurology, July 26, 2004 -
Views & Reviews
Outcome in adult low-grade gliomaThe impact of prognostic factors and treatmentDavid Schiff, Paul D. Brown, Caterina Giannini et al.Neurology, September 24, 2007 -
Article
Low-grade oligodendroglioma responds to chemotherapyWarren P. Mason, George S. Krol, Lisa M. DeAngelis et al.Neurology, January 01, 1996